CTA-01 (Cytoarm/SL BIO)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameCTA-01 (Cytoarm/SL BIO)
Drug Alias NameCTA-01 (Cytoarm)CTA-001 (Cytoarm)SL-AT001CTA-01CTA-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCytoarm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSL LINK Co LtdCytoarm Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A